Five-year follow-up data from orthopedic stem cell programs has been released, and the headline result is durability: 87% of treated patients reported sustained pain relief and improved joint function half a decade after their single-course treatment.
The programs use mesenchymal stem cells — most commonly harvested from the patient's own bone marrow or adipose tissue — injected precisely into damaged cartilage, tendon or bone under imaging guidance. Because the cells come from the patient, rejection risk is minimal and the procedure is day-surgery rather than an inpatient operation.
Equally important is what the data says about who benefits most: patients with moderate (grade 2-3) osteoarthritis saw the strongest gains, while advanced 'bone-on-bone' cases still achieved better outcomes from joint replacement. Honest patient selection remains the core of good regenerative medicine.
International patients considering stem cell therapy should ask three questions: What is the cell source and processing standard? Is there five-year published follow-up? And what does the program recommend if the treatment does not deliver? Our partner programs answer all three in writing, before any payment.